Global pharmaceutical firm Boehringer Ingelheim recently provided an overview of its “significant” progress during 2017 in partnership with other institutions.
The company customarily develops about half of its early and mid-stage work in collaboration with other organizations. This year brought joint ventures with the University of California at Los Angeles (UCLA), Siamab Therapeutics and AbeXXa Biologics, according to a Boehringer press release.
The company's collaborations produced vaccine technologies and therapeutic treatments targeting tumors at various levels, according to the release.
“Boehringer Ingelheim believes partnerships are vital to innovation as it leverages human talent and resources to speed research,” Dr. Jorg Barth, Boehringer Ingelheim’s head of therapeutic oncology, said in the release. “We highly value our partners’ creativity and the opportunities and resources they offer as we work together to tackle the biggest challenges in oncology.”
Barth said mutual cooperation with industry colleagues serves the firm’s goals.
“We believe the best way to accelerate innovation is by combining our in-house capabilities in collaboration with industry and academia,” he said. “Winning the fight against cancer will only be achieved with novel approaches and genuine scientific breakthroughs.”
Boehringer Ingelheim's U.S. headquarters are in Ridgefield, Connecticut.
